NGM: AI 评分 49/100 — AI 分析 (4月 2026)

概要：

NGM是做什么的？

NGM的投资论点是什么？

NGM在哪个行业运营？

NGM有哪些增长机遇？

• Aldafermin for NASH: The NASH market is expected to grow significantly in the coming years, driven by the rising prevalence of obesity and diabetes. Aldafermin, currently in Phase IIb trials, has the potential to capture a significant share of this market if approved. Success in clinical trials and subsequent commercialization could generate substantial revenue for NGM.
• MK-3655 for Type 2 Diabetes and NASH: MK-3655, also in Phase IIb trials, targets both type 2 diabetes and NASH, offering a dual-pronged approach to these metabolic diseases. The global type 2 diabetes market is substantial, and a successful therapy could provide significant growth opportunities for NGM. Positive clinical data could attract further partnerships and investment.
• NGM621 for Geographic Atrophy: NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials, targets geographic atrophy, a significant unmet need in retinal diseases. The market for geographic atrophy therapies is growing, and successful development of NGM621 could position NGM as a key player in this space. Data readouts from the Phase II trials will be a key catalyst.
• NGM707 for Advanced Solid Tumors: NGM707, a dual antagonist monoclonal antibody, is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors. The oncology market is vast, and successful development of NGM707 could provide significant growth opportunities for NGM. Early clinical data will be crucial in determining the future of this program.
• Strategic Collaborations with Merck: NGM's collaborations with Merck provide access to resources, expertise, and potential revenue streams. These partnerships focus on developing novel medicines for retinal and cardiovascular metabolic (CVM) diseases, including heart failure. Continued success in these collaborations could lead to further expansion of NGM's pipeline and market reach.

• Market capitalization of $0.13 billion indicates potential for growth if clinical trials are successful.
• Gross margin of 49.7% demonstrates the company's ability to generate revenue from its collaborations and early-stage assets.
• P/E ratio of -0.89 reflects the company's current lack of profitability due to ongoing R&D investments.
• Beta of 1.26 suggests the stock is more volatile than the market average.
• Strategic collaborations with Merck provide financial resources and validation of NGM's technology.

NGM提供哪些产品和服务？

• Discovers and develops novel therapeutics.
• Focuses on liver and metabolic diseases.
• Develops treatments for retinal diseases.
• Creates therapies for cancer.
• Conducts clinical trials to evaluate product candidates.
• Partners with pharmaceutical companies for research and development.

NGM如何赚钱？

• Develops and out-licenses novel therapeutics.
• Generates revenue through research collaborations and licensing agreements.
• Advances product candidates through clinical trials.
• Seeks partnerships for commercialization of approved therapies.

• Patients with liver diseases, such as NASH.
• Patients with metabolic diseases, such as type 2 diabetes.
• Patients with retinal diseases, such as geographic atrophy.
• Patients with advanced solid tumors.
• Pharmaceutical companies through collaborations and licensing agreements.

• Proprietary drug discovery platform.
• Strong intellectual property portfolio.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team with expertise in drug development.

什么因素可能推动NGM股价上涨？

• Upcoming: Data readout from Phase IIb clinical trial of Aldafermin for NASH.
• Upcoming: Data readout from Phase IIb clinical trial of MK-3655 for type 2 diabetes and NASH.
• Ongoing: Enrollment and progress in Phase I/II clinical trials of NGM120 and NGM707.
• Ongoing: Advancement of NGM621 through Phase II clinical trials for geographic atrophy.
• Ongoing: Potential for new collaborations and licensing agreements.

NGM的主要风险是什么？

• Potential: Clinical trial failures could significantly impact the company's valuation.
• Potential: Regulatory delays or rejection of product candidates.
• Ongoing: Competition from other companies developing therapies for the same indications.
• Ongoing: Dependence on collaborations with Merck for financial support and development expertise.
• Potential: Difficulty in raising additional capital to fund ongoing research and development.

NGM的核心优势是什么？

• Promising pipeline of novel therapeutics.
• Strategic collaborations with Merck.
• Experienced management team.
• Strong intellectual property portfolio.

NGM的劣势是什么？

• Limited financial resources.
• Dependence on clinical trial outcomes.
• Lack of commercialized products.
• High cash burn rate.

NGM有哪些机遇？

• Successful clinical trial results.
• Expansion of pipeline through internal discovery and collaborations.
• Partnerships for commercialization of approved therapies.
• Growing market for NASH and other target diseases.

NGM面临哪些威胁？

• Clinical trial failures.
• Regulatory hurdles.
• Competition from other pharmaceutical and biotechnology companies.
• Patent challenges.

NGM的竞争对手是谁？

• aTyr Pharma — Focuses on tRNA synthetase biology. — (ATYR)
• DBTx — Developing novel therapeutics for cancer and other diseases. — (DBTX)
• Graybug Vision — Focuses on retinal diseases. — (GRAY)
• Kintara Therapeutics — Developing therapies for cancer. — (KNTE)
• Pardes Biosciences — Developing oral antiviral therapies. — (PRDS)

Key Metrics

• Price: $1.54 (-1.28%)
• Market Cap: $129.0M
• MoonshotScore: 49/100

Company Profile

• CEO: David J. Woodhouse
• Headquarters: South San Francisco, CA, US
• Employees: 138
• Founded: 2019

AI Insight